Cargando…
Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND MET...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790563/ https://www.ncbi.nlm.nih.gov/pubmed/35064953 http://dx.doi.org/10.1111/bju.15697 |
_version_ | 1784859206297321472 |
---|---|
author | van Hoogstraten, Lisa M.C. Witjes, J. Alfred Meijer, Richard P. Ripping, Theodora M. Kiemeney, Lambertus A. Aben, Katja K.H. |
author_facet | van Hoogstraten, Lisa M.C. Witjes, J. Alfred Meijer, Richard P. Ripping, Theodora M. Kiemeney, Lambertus A. Aben, Katja K.H. |
author_sort | van Hoogstraten, Lisa M.C. |
collection | PubMed |
description | OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. CONCLUSION: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment. |
format | Online Article Text |
id | pubmed-9790563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97905632022-12-28 Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent van Hoogstraten, Lisa M.C. Witjes, J. Alfred Meijer, Richard P. Ripping, Theodora M. Kiemeney, Lambertus A. Aben, Katja K.H. BJU Int Original Articles OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. CONCLUSION: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment. John Wiley and Sons Inc. 2022-02-08 2022-12 /pmc/articles/PMC9790563/ /pubmed/35064953 http://dx.doi.org/10.1111/bju.15697 Text en © 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles van Hoogstraten, Lisa M.C. Witjes, J. Alfred Meijer, Richard P. Ripping, Theodora M. Kiemeney, Lambertus A. Aben, Katja K.H. Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title | Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title_full | Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title_fullStr | Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title_full_unstemmed | Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title_short | Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
title_sort | non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790563/ https://www.ncbi.nlm.nih.gov/pubmed/35064953 http://dx.doi.org/10.1111/bju.15697 |
work_keys_str_mv | AT vanhoogstratenlisamc nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT witjesjalfred nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT meijerrichardp nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT rippingtheodoram nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT kiemeneylambertusa nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent AT abenkatjakh nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent |